You are here

Nanowire Sensor Array-based Assay for Early Diagnosis of Alzheimer's Disease

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43AG046059-01A1
Agency Tracking Number: R43AG046059
Amount: $224,999.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NIA
Solicitation Number: PA13-234
Timeline
Solicitation Year: 2014
Award Year: 2014
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
2531 W 237TH ST, STE 127
TORRANCE, CA 90505-5245
United States
DUNS: 114060861
HUBZone Owned: No
Woman Owned: Yes
Socially and Economically Disadvantaged: No
Principal Investigator
 MAKSUDUL ALAM
 (310) 530-2011
 maksudul.alam-1@innosense.us
Business Contact
 KISHOLOY GOSWAMI
Phone: (310) 530-2011
Email: kisholoy.goswami@innosense.us
Research Institution
 Stub
Abstract

DESCRIPTION (provided by applicant): Over 5 million Americans are currently believed to have Alzheimer's disease (AD), the most common form of dementia. This number could reach 16 million by 2050. AD is a terminal, progressive brain disorder with no knowncause or cure. AD leads to memory loss, confusion, impaired judgment, personality changes, disorientation, and the inability to communicate. The Alzheimer's Association estimates that 450,000 people will die with Alzheimer's, meaning they will die after developing the disease. The cost of care is estimated to be 203 billion in the United States in 2013. In addition, 15.4 million Americans provide unpaid care valued at 216 billion for persons with Alzheimer's and other forms of dementia. Currently, there is no definitive clinical diagnosis for AD other than a postmortem autopsy. Because early diagnosis could enable better planned and coordinated care, there is an urgent need to develop a cost-effective, highly sensitive and selective early stage diagnostic

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government